These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30846478)

  • 41. Metastatic squamous cell carcinoma resembling angiosarcoma complicating dystrophic epidermolysis bullosa.
    McGrath JA; Schofield OM; Mayou BJ; McKee PH; Eady RA
    Dermatologica; 1991; 182(4):235-8. PubMed ID: 1884860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma.
    Dayal JHS; Mason SM; Salas-Alanis JC; McGrath JA; Taylor RG; Mellerio JE; Blyth K; South AP; Inman GJ
    Br J Dermatol; 2021 Apr; 184(4):697-708. PubMed ID: 32726455
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
    Trefzer L; Hess ME; Scholten L; Technau-Hafsi K; Meiss F; Boerries M; Has C; Rafei-Shamsabadi D
    Acta Derm Venereol; 2023 Jun; 103():adv4870. PubMed ID: 37338146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa: report of eight tumours in four patients.
    Bosch RJ; Gallardo MA; Ruiz del Portal G; Snchez P; Arce MF; Herrera E
    J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):198-204. PubMed ID: 10642056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
    Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
    Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anchorless keratinocyte survival: an emerging pathogenic mechanism for squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
    Rodeck U; Fertala A; Uitto J
    Exp Dermatol; 2007 Jun; 16(6):465-7. PubMed ID: 17518985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development.
    Guerra L; Odorisio T; Zambruno G; Castiglia D
    Matrix Biol; 2017 Nov; 63():1-10. PubMed ID: 28126522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa.
    Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G
    Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Squamous cell carcinoma in a family with dominant dystrophic epidermolysis bullosa: a molecular genetic study.
    Christiano AM; Crollick J; Pincus S; Uitto J
    Exp Dermatol; 1999 Apr; 8(2):146-52. PubMed ID: 10232408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma.
    Kivisaari AK; Kallajoki M; Ala-aho R; McGrath JA; Bauer JW; Königová R; Medvecz M; Beckert W; Grénman R; Kähäri VM
    Br J Dermatol; 2010 Oct; 163(4):726-35. PubMed ID: 20586780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The clinical spectrum of dystrophic epidermolysis bullosa.
    Horn HM; Tidman MJ
    Br J Dermatol; 2002 Feb; 146(2):267-74. PubMed ID: 11903238
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
    Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
    Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
    Duong T; Wong D; Barrett A; Price H
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Verruciform xanthoma in recessive dystrophic epidermolysis bullosa and keratitis-ichthyosis-deafness syndrome: Report of two cases and a review of the literature.
    Evan-Browning E; Rork J; O'Donnell P; Elaba Z; Deng A; Wiss K
    Pediatr Dermatol; 2020 Jan; 37(1):176-179. PubMed ID: 31710113
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006.
    Fine JD; Johnson LB; Weiner M; Li KP; Suchindran C
    J Am Acad Dermatol; 2009 Feb; 60(2):203-11. PubMed ID: 19026465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.
    Atanasova VS; Russell RJ; Webster TG; Cao Q; Agarwal P; Lim YZ; Krishnan S; Fuentes I; Guttmann-Gruber C; McGrath JA; Salas-Alanis JC; Fertala A; South AP
    J Invest Dermatol; 2019 Jul; 139(7):1497-1505.e5. PubMed ID: 30684555
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
    Bowles DW; Diamond JR; Lam ET; Weekes CD; Astling DP; Anderson RT; Leong S; Gore L; Varella-Garcia M; Vogler BW; Keysar SB; Freas E; Aisner DL; Ren C; Tan AC; Wilhelm F; Maniar M; Eckhardt SG; Messersmith WA; Jimeno A
    Clin Cancer Res; 2014 Mar; 20(6):1656-65. PubMed ID: 24493827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Good clinical response to cemiplimab in a young patient with locally advanced cutaneous squamous cell carcinoma on preexisting recessive dystrophic epidermolysis bullosa.
    Ciurescu D; Condruz S; Irimie M
    Acta Dermatovenerol Alp Pannonica Adriat; 2024 Sep; 33(3):145-149. PubMed ID: 38808531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma.
    Ma H; Nie C; Chen Y; Li J; Xie Y; Tang Z; Gao Y; Ai S; Mao Y; Sun Q; Lu R
    Oncol Res; 2021 Sep; 28(7):745-761. PubMed ID: 33573708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.